Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy

NCT06255223 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT06255223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06255223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2023
Completion date
September 1, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitor, radiotherapy, renal cell carcinoma